Article Text

Download PDFPDF
Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision
  1. Denis Angoulvant1,
  2. Theodora Bejan Angoulvant2,
  3. Laurent Fauchier1
  1. 1Service de Cardiologie, Pôle Cœur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Université François Rabelais, Tours, France
  2. 2Service de Pharmacologie clinique, Centre Hospitalier Universitaire Bretonneau et Faculté de Médecine, Université François Rabelais, Tours, France
  1. Correspondence to Denis Angoulvant, Service de Cardiologie, Pole Cœur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau, Tours 37044, France; d.angoulvant{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The 2014 European Society of Cardiology (ESC) guidelines recommend 12 months of dual antiplatelet therapy (DAPT) favouring combination of aspirin and prasugrel or aspirin and ticagrelor over aspirin and clopidogrel after acute coronary syndrome (ACS).1 The rationale behind these recommendations is based on prospective randomised trials investigating the efficacy of both combinations against aspirin and clopidogrel. The risk-to-benefit ratios of these strategies were estimated from clinical trials investigating their efficacy on major cardiovascular events and their safety on major bleeding events.1 Not surprisingly, both new P2Y12 inhibitors induced more bleeding, but with different patterns. In ST-segment elevation myocardial infarction (STEMI) patients, most frequent fatal bleeding events with prasugrel were particularly noticeable in older or underweight patients and in those with previous cerebrovascular disease. Ticagrelor increased the risk of non-coronary artery bypass graft (CABG)-related major bleeding events, including fatal intracranial bleeding.

Klingenberg et al2 now report in their Heart paper the results of a recent Swiss cohort study investigating ‘in real life’ the safety profile of prasugrel and clopidogrel, both combined with aspirin, after ACS. In their study data, 2148 patients were analysed using a propensity score to assess and compare 1-year safety. No significant differences were observed between antiplatelet regimen regarding major bleeding, regardless of the classification used: TIMI, GUSTO and BARC. Patients receiving clopidogrel were significantly older, more likely to be women, and more likely to have diabetes and chronic renal failure. Patients receiving prasugrel had significantly more STEMI at clinical presentation and had more stent implantation during the index procedure. As expected, …

View Full Text


  • Contributors All authors contributed to the drafting of the editorial, revising the manuscript critically for intellectual content, and all approved the final manuscript.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Coronary artery disease
    Roland Klingenberg Dik Heg Lorenz Räber David Carballo David Nanchen Baris Gencer Reto Auer Milosz Jaguszewski Barbara E Stähli Philipp Jakob Christian Templin Giulio G Stefanini Bernhard Meier Pierre Vogt Marco Roffi Willibald Maier Ulf Landmesser Nicolas Rodondi François Mach Stephan Windecker Peter Jüni Thomas F Lüscher Christian M Matter